Read by QxMD icon Read

Prostate biopsy

Andrew K Leung, Lee Hugar, Dattatraya Patil, Lisa Wong, Bradley Carthon, Kenneth Carney, George Birdsong, Kelvin A Moses, Viraj A Master
OBJECTIVE: To characterize men presenting to a tertiary care safety-net hospital with prostate-specific antigen (PSA) values ≥100 ng/mL and identify a potential population for targeted PSA screening. METHODS: Retrospective review of 100 randomly selected patients out of 204 total who presented to Grady Memorial Hospital from 2004-2011 with initial PSA≥100 ng/mL was performed. Demographics, disease characteristics, and survival status were obtained via the Tumor Registry and a combination of electronic medical records and older paper charts, with missing data from paper charts excluded on analyses...
April 12, 2018: Urology
Daniel W Lin, E David Crawford, Thomas Keane, Brent Evans, Julia Reid, Saradha Rajamani, Krystal Brown, Alexander Gutin, Jonathan Tward, Peter Scardino, Michael Brawer, Steven Stone, Jack Cuzick
BACKGROUND: A combined clinical cell-cycle risk (CCR) score that incorporates prognostic molecular and clinical information has been recently developed and validated to improve prostate cancer mortality (PCM) risk stratification over clinical features alone. As clinical features are currently used to select men for active surveillance (AS), we developed and validated a CCR score threshold to improve the identification of men with low-risk disease who are appropriate for AS. METHODS: The score threshold was selected based on the 90th percentile of CCR scores among men who might typically be considered for AS based on NCCN low/favorable-intermediate risk criteria (CCR = 0...
April 11, 2018: Urologic Oncology
Nicole E Curci, Brian R Lane, Prasad R Shankar, Sabrina L Noyes, Andrew K Moriarty, Anthony Kubat, Chris Brede, Jeffrey S Montgomery, Gregory B Auffenberg, David C Miller, James E Montie, Arvin K George, Matthew S Davenport
OBJECTIVE: To evaluate the integration of 3T non-endorectal-coil multiparametric prostate MRI (mpMRI) at two high-volume practices that routinely use mpMRI in the setting of active surveillance. MATERIALS AND METHODS: This was an IRB-approved, HIPAA-compliant, dual-institution retrospective cohort study. Subjects undergoing 3T mpMRI without endorectal coil at either study institution over a 13-month period (8/1/2015-8/31/2016) were selected based on pre-defined criteria: clinical T1/T2 Gleason 6 prostate cancer, PSA<15 ng/mL, ≥40 years-old, mpMRI within 2 years of prostate biopsy, PI-RADS v2 score assigned...
April 10, 2018: Urology
Matthew D Greer, Nathan Lay, Joanna H Shih, Tristan Barrett, Leonardo Kayat Bittencourt, Samuel Borofsky, Ismail Kabakus, Yan Mee Law, Jamie Marko, Haytham Shebel, Francesca V Mertan, Maria J Merino, Bradford J Wood, Peter A Pinto, Ronald M Summers, Peter L Choyke, Baris Turkbey
OBJECTIVES: To evaluate if computer-aided diagnosis (CAD) prior to prostate multi-parametric MRI (mpMRI) can improve sensitivity and agreement between radiologists. METHODS: Nine radiologists (three each high, intermediate, low experience) from eight institutions participated. A total of 163 patients with 3-T mpMRI from 4/2012 to 6/2015 were included: 110 cancer patients with prostatectomy after mpMRI, 53 patients with no lesions on mpMRI and negative TRUS-guided biopsy...
April 12, 2018: European Radiology
Luis Javier Martinez-Gonzalez, Manrique Pascual Geler, Inmaculada Robles Fernandez, Jose Manuel Cozar, Jose Antonio Lorente, Maria Jesus Alvarez Cubero
BACKGROUND: Somatic mutations have been related to the highest incidence of metastatic disease and different treatment responses. The molecular cause of prostate cancer (PC) is still unclear; however, its progression involves alterations in oncogenes and tumor suppressor genes as well as somatic mutations such as the ones in PIK3CA gene. A high percentage of PC is considered sporadic, which means that the damage to the genes occurs by chance after birth (mainly somatic mutations will drive the cancer event)...
April 9, 2018: Urologic Oncology
R J Bryant, B Yang, Y Philippou, K Lam, M Obiakor, J Ayers, V Chiocchia, F Gleeson, R MacPherson, C Verrill, P Sooriakumaran, F C Hamdy, S F Brewster
OBJECTIVES: To determine whether replacement of protocol-driven repeat prostate biopsy (PB) with multiparametric magnetic resonance imaging (mpMRI) +/- targeted repeat prostate biopsy (TB) in evaluating men on active surveillance (AS) for low-volume low- to intermediate-risk prostate cancer (PCa) altered the likelihood or time to treatment, or reduced the number of repeat biopsies required to trigger treatment. PATIENTS AND METHODS: 445 patients underwent AS from 2010-2016 at our institution with median follow-up of 2...
April 12, 2018: BJU International
Gazala Perveen, Geetanjali Arora, Nishikant Avinash Damle, Meghana Prabhu, Saurabh Arora, Madhavi Tripathi, Chandrasekhar Bal, Praveen Kumar, Rajeev Kumar, Prabhjot Singh
Rationale: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is widely used for imaging of prostate cancer (PC) nowadays. However, appearance of bladder activity many a times hampers lesion detection vis-a-vis primary as well as regional nodes. We aimed to assess if early dynamic PET/CT can be a potential solution to this issue. Methodology: A total of 15 biopsy-proven PC patients who were referred to our department for 68 Ga-PSMA PET/CT for staging/restaging were prospectively studied...
April 2018: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
Samrad Ghavimi, Hamidreza Abdi, Jennifer Waterhouse, Richard Savdie, Silvia Chang, Alison Harris, Lindsay Machan, Martin Gleave, Alan So, Larry Goldenberg, Peter C Black
INTRODUCTION: The natural history of prostatic lesions identified on multiparametric magnetic resonance imaging (mpMRI) is largely unknown. We aimed to describe changes observed over time on serial MRI. METHODS: All patients with ≥2 MRI studies between 2008 and 2015 at our institution were identified. MRI progression was defined as an increase in Prostate Imaging Reporting and Data System (PI-RADS; version 2) or size of existing lesions, or the appearance of a new lesion PIRADS ≥4...
April 6, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Kyung Chul Son, Ho Seok Chung, Seung Il Jung, Myung Soo Kim, Eu Chang Hwang, Jin Woong Kim, Dong Deuk Kwon
BACKGROUND: To investigate whether addition of amikacin to fluoroquinolone (FQ) antimicrobial prophylaxis reduces infections after transrectal ultrasound-guided prostate biopsy (TRUSPB). METHODS: A total of 503 patients undergoing rectal swab were divided into three groups. Patients with FQ-sensitive rectal flora (group 1, n = 248) were administered ciprofloxacin before TRUSPB, and patients with FQ-resistant rectal flora were either administered ciprofloxacin (group 2, n = 97) or amikacin and ciprofloxacin (group 3, n = 158) before TRUSPB...
April 9, 2018: Journal of Korean Medical Science
Daniel Rohrbach, Brian Wodlinger, Jerrold Wen, Jonathan Mamou, Ernest Feleppa
Currently, biopsies guided by transrectal ultrasound (TRUS) are the only method for definitive diagnosis of prostate cancer. Studies by our group suggest that quantitative ultrasound (QUS) could provide a more sensitive means of targeting biopsies and directing focal treatments to cancer-suspicious regions in the prostate. Previous studies have utilized ultrasound signals at typical clinical frequencies, i.e., in the 6-MHz range. In the present study, a 29-MHz, TRUS, micro-ultrasound system and transducer (ExactVu micro-ultrasound, Exact Imaging, Markham, Canada) was used to acquire radio frequency data from 163 patients immediately before 12-core biopsy procedures, comprising 1956 cores...
April 4, 2018: Ultrasound in Medicine & Biology
Dominic H Moon, Daniel P Lindsay, Seungpyo Hong, Andrew Z Wang
Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and entered circulation with potential to initiate a site of metastasis. Currently, CTC detection using CellSearch is cleared by the Food and Drug Administration for monitoring metastatic breast, prostate, and colorectal cancers as a prognostic biomarker for progression-free and overall survival. Accumulating evidence suggests CTCs have similar prognostic value in other metastatic and non-metastatic settings. Current research efforts are focused on extending the utility of CTCs beyond a prognostic biomarker to help guide clinical decision-making...
April 4, 2018: Advanced Drug Delivery Reviews
Ketan K Badani, Balaji N Reddy, Eric J Moskowitz, David J Paulucci, Alp Tuna Beksac, Alberto Martini, Michael J Whalen, Douglas W Skarecky, Linda My Huynh, Thomas E Ahlering
OBJECTIVES: Seminal vesicle invasion (SVI) is a risk factor for poor oncologic outcome in patients with prostate cancer. Modifications to the pelvic lymph node dissection (PLND) during radical prostatectomy (RP) have been reported to have a therapeutic benefit. The present study is the first to determine if lymph node yield (LNY) is associated with a lower risk of biochemical recurrence (BCR) for men with SVI. METHODS: A total of 220 patients from 2 high-volume institutions who underwent RP without adjuvant treatment between 1990 and 2015 and had prostate cancer with SVI (i...
April 3, 2018: Urologic Oncology
Angel Fernandez-Flores, David S Cassarino
Pilomatrical (pilomatrix) carcinoma is a rare cutaneous adnexal tumor with matrical differentiation and recurrent and metastatic potential. Sarcomatoid pilomatrix carcinoma is a rare variant which shows a sarcomatoid component intermingling with the epithelial one. There are only four cases previously published. We present an additional case on the hand of a 78 year-old man which appeared as a 6 mm hyperkeratotic ─focally ulcerated─ plaque. A shave biopsy demonstrated a dermal infiltrative neoplasm, composed of markedly atypical-appearing basaloid cells with focal necrotic/ghost cells, as well as an intimately associated population of atypical oval to spindle-shaped cells...
April 6, 2018: Journal of Cutaneous Pathology
Maha Hussain, Catherine M Tangen, Ian M Thompson, Gregory P Swanson, David P Wood, Wael Sakr, Nancy A Dawson, Naomi B Haas, Thomas W Flaig, Tanya B Dorff, Daniel W Lin, E David Crawford, David I Quinn, Nicholas J Vogelzang, L Michael Glode
Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostate cancer with one or more high-risk factors after radical prostatectomy (Gleason score [GS] ≥ 8; pT3b, pT4, or pN+ disease; GS 7 and positive margins; or preoperative prostate-specific antigen [PSA] > 15 ng/mL, biopsy GS score > 7, or PSA > 10 ng/mL plus biopsy GS > 6...
April 6, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Sami-Ramzi Leyh-Bannurah, Dominique Trudel, Mathieu Latour, Emanuele Zaffuto, Andree-Anne Grosset, Christine Tam, Veronique Ouellet, Markus Graefen, Lars Budäus, Armen G Aprikian, Louis Lacombe, Neil E Fleshner, Martin E Gleave, Anne-Marie Mes-Masson, Fred Saad, Pierre I Karakiewicz
To test the agreement between high-grade PCa at RP and TMA, and the ability of TMA to predict BCR. Validation of concordance between tissue microarray (TMA) and radical prostatectomy (RP) high-grade prostate cancer (PCa) is crucial because latter determines the treated natural history of PCa. We hypothesized that TMA Gleason score is in agreement with RP pathology and capable of accurately predicting biochemical recurrence (BCR). Data were provided from a multi-institutional Canadian sample of 1333 TMA and RP specimens with complete clinicopathological data...
April 6, 2018: Pathology Oncology Research: POR
Daniel Gunda, Ibrahim Kido, Semvua Kilonzo, Igembe Nkandala, John Igenge, Bonaventura Mpondo
Background: Prostatic carcinoma carries a high morbidity and mortality if it is not diagnosed early. In resource limited countries, patients are at increased risk of being diagnosed late as they are operated for presumed benign prostatic hyperplasia. The information on the magnitude and risk factors of this problem in our setting could assist in the overall optimization of care of patients at risk. Methods: A retrospective study of patients who underwent prostatectomy for presumed benign prostatic enlargement was done at Bugando University Hspital in Tanzania...
January 2018: Ethiopian Journal of Health Sciences
Jay H Fowke, Saundra S Motley
The roles of obesity, metabolic dysregulation, and systemic inflammation to advance prostate carcinogenesis are unclear. This study investigates metabolic and inflammatory factors in the transition from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer (PC). We prospectively followed 160 men diagnosed with HGPIN at biopsy, and therefore at high-risk and clinically monitored for PC. Analyses investigated body mass index (BMI), waist circumference, waist-hip ratio, height, fat mass, lean mass % body fat, NSAIDs, statins, metformin, diabetes, hypertension, hypercholesterolemia representing metabolic dysregulation on the risk of a PC diagnosis during follow-up...
April 3, 2018: Carcinogenesis
Mehmet Demir, Yigit Akin, Kubra Asena Kapakin Terim, Mehmet Gulum, Evren Buyukfirat, Halil Ciftci, Ercan Yeni
OBJECTIVES: Apoptosis effect of oral alpha-blockers is known in the prostate. Apoptosis index of silodosin has not been proved, yet. Aims are to present apoptosis index of silodosin in prostate and to compare this with other currently used alpha-blocker's apoptosis indexes together with their clinical effects. MATERIALS AND METHODS: Benign prostatic hyperplasia (BPH) patients were enrolled among those admitted to urology outpatient clinic between June 2014 and June 2015...
March 18, 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Andrew W Tam, Johnathan Khusid, Igor Inoyatov, Adan Z Becerra, Jonathan Davila, Jyoti D Chouhan, Jeffrey P Weiss, Llewellyn M Hyacinthe, Brian K McNeil, Andrew G Winer
INTRODUCTION: We compared characteristics of patients undergoing prostate biopsy in a high-risk inner city population before and after the 2012 USPSTF recommendation against PSA based prostate cancer screening to determine its effect on prostate biopsy practices. MATERIALS AND METHODS: This was a retrospective study including patients who received biopsies after an abnormal PSA measurement from October 2008-December 2015. Patients with previously diagnosed prostate cancer were excluded...
March 15, 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Fabrizio Dal Moro, Giovanni Zecchini, Alessandro Morlacco, Marina Paola Gardiman, Carmelo Salvino Lacognata, Alberto Lauro, Massimo Rugge, Tommaso Prayer Galetti, Filiberto Zattoni
BACKGROUND: Multiparametric-magnetic resonance imaging (mpMRI) can accurately detect high-grade and larger prostate cancers (PC). AIMS: To evaluate the ability of 1.5 T magnetic field mpMRI-targeted Prostate Biopsies (PBx) in predicting PC in comparison with blind 24-core saturation PBx (sPBx). METHODS: We prospectively collected data from patients undergoing transrectal sPBx and, if needed, targeted PBx of suspected lesions based on the 16-'region-of-interest' (ROI) PI-RADS graph...
April 3, 2018: Aging Clinical and Experimental Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"